跳至主要内容
临床试验/NCT06527560
NCT06527560尚未招募4 期

Ensaio clínico Entre Cefuroxima Por Via Oral ou Por Via Intravenosa em Gestantes Com Pielonefrite

Hospital de Clinicas de Porto Alegre1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
尚未招募
入组人数
100
试验地点
1
主要终点
Clinical improvement

研究概览

简要总结

The goal of this clinical trial is to compare rates of cure in pregnant women with pyelonephritis. The main question aims to answer:

Can we treat pyelonephritis in pregnancy with oral cefuroxime alone?

Pregnant women with pyelonephritis treated with intravenous cefuroxime will be the comparator.

Participants will be asked to accept participation in the study and will be randomly allocated to one of the two arms:

  • Intravenous cefuroxime 750 mg every 8 hours + oral placebo every 12 hours
  • Oral cefuroxime 500 mg every 12 hours + intravenous saline solution every 8 hours

详细描述

Urinary tract infections are common during pregnancy and can lead to pyelonephritis, a condition associated with morbidity in both the fetus and the pregnant woman. At HCPA, intravenous cefuroxime has been used until the antibiogram results from the pregnant woman's urine culture are available. However, this treatment requires hospitalization, which is financially burdensome and can affect the well-being of the pregnant woman. Despite this, there are not enough studies to investigate the use of oral cefuroxime as an initial treatment.

Objective

To compare the efficacy of cefuroxime administered orally versus intravenously in curing pyelonephritis during pregnancy, aiming to test the non-inferiority of the oral treatment.

Method: A randomized, prospective, triple-blind, two-arm study will be conducted. Pregnant women with pyelonephritis who agree to participate in the study at the time of hospitalization will receive the treatment: I) cefuroxime axetil 750mg IV every 8 hours and a placebo capsule 500mg; or II) 500mg orally every 12 hours and IV saline solution. These patients will be followed until the outcome is determined. After 48 hours in good clinical condition, the patients will be discharged and will continue treatment with cefuroxime axetil 500mg orally every 12 hours for 14 days. To analyze the difference in means and proportions with confidence intervals, Student's t-test will be performed, while nominal data will be analyzed using the chi-square test.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

Patients, care providers and investigators will not be aware of the treatment arm. Statistical analysis will be performed using pre-established criteria to access coded treatment

入排标准

年龄范围
18 Years 至 48 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women aged 18 years or older and less than 20 weeks of gestational age, determined by ultrasound or the date of last menstruation, who come to the HCPA emergency department with a clinical diagnosis of pyelonephritis in pregnancy, defined as:
  • Presence of lower back pain associated with
  • Dysuria with leukocyturia, or hematuria or nitrite in the urine test with at least one of the criteria below:
  • Leukocytosis (> 14,000 leukocytes/mL)
  • Warm extremities, thready pulse, and tachycardia (HR > 110 bpm)
  • Cyanosis and/or pallor
  • Tachypnea (RR > 30 breaths/min)
  • Arterial hypotension (SBP < 90mmHg)
  • Positive costovertebral angle tenderness
  • Urine culture with colony growth
  • Hyperthermia (≥ 37.8°C)"

排除标准

  • Do not wish to participate in the project.
  • Used antimicrobials prior to hospitalization (3-day period).
  • those who are allergic to cefuroxime.
  • Have a urine culture antibiogram resistant to cefuroxime AND absence of clinical improvement (in this case, will be excluded as modified intention to treat).
  • Have a diagnosis other than pyelonephritis, for example, appendicitis.
  • those in septic shock, defined as:
  • the need for vasopressor to maintain a mean arterial pressure ≥ 65 mmHg and lactate > 2 mmol/l or 2 points on qSOFA. qSOFA will be considered positive when at least two of the following clinical criteria are present:
  • Respiratory rate greater than or equal to 22 breaths per minute;
  • Altered level of consciousness (Glasgow Coma Scale score less than 15);
  • Systolic blood pressure less than or equal to 100 mmHg.

研究组 & 干预措施

Intravenous cefuroxime

Active Comparator

Intravenous cefuroxime 750 mg every 8 hours + oral placebo every 12 hours

干预措施: Cefuroxime (Drug)

Oral axetil cefuroxime

Experimental

Oral axetil cefuroxime 500 mg every 12 hours + intravenous saline solution every 8 hours

干预措施: Cefuroxime Axetil (Drug)

结局指标

主要结局

Clinical improvement

时间窗: 3 days

No fever, improvement of lower back pain

Negative urine culture

时间窗: 21 days

No growth of pathogenic bacteria in the urine culture

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验